【投后新闻】万春抗肿瘤创新药临床最新进展-Shenzhen Sangel Venture Capital Co.,Ltd.

Your Current Location：Home>News>项目动态

【投后新闻】万春抗肿瘤创新药临床最新进展

10-27,2017

Shenzhen Sangel Venture Capital Co.,Ltd.

ICP15012769

Shenzhen Sangel Venture Capital Co.,Ltd.

Address：Shenzhen Bay Venture Capital Building, Nanshan District, Shenzhen 2401/2402
Tel：0755-26069007 E-mail：sangel@sangelvc.com